To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Key Points Pfizer will buy Metsera for at least $47.50 per share. Pfizer could end up paying closer to $70 per share. Pfizer wants to sell GLP-1 weight loss drugs, and Metsera has four such candidates. 10 stocks we like better than Pfizer › Pfizer (NYSE: PFE), the one-time COVID vaccine hero turned Ozempic craze zero, is marching higher Monday after announcing it will try to recover from its danuglipron setback by buying another drug company with weight loss dreams. As of 12:25 p.m. ET, Pfizer st ...

Pfizer Inc. will pay $4.9 billion for the obesity startup Metsera Inc. in a bid to catch up to rival drugmakers after failing to compete with its own weight-loss medications. The US drugmaker agreed to buy Metsera for $47.50 in cash per share, and further payments of up to $22.50 per share if three specific and regulatory milestones are met, it said Monday, with a total potential value of $7.3 billion. The deal represents a 43% premium to Metsera's closing share price on Friday. Bloomberg's Sam Fazeli repo ...

Pfizer has acquired Metsera for $4.9bn, as the drugmaker targets longer-lasting glucagon-like peptide-1 receptor agonists (GLP-1RAs) to cement market share in the burgeoning weight loss treatment sector. Pfizer has agreed to buy all of Metsera’s shares for a price of $47.50 each, representing a 43% premium to Metsera’s closing share price of $33.32 on 19 September. The deal, forecast to close in Q4 2025, also includes potential additional payments of up to $22.50 per share in cash tied to three specific c ...

SAN DIEGO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP, has launched an investigation into whether the board members of Metsera, Inc. (NASDAQ: MTSR) breached their fiduciary duties in connection with the proposed sale of the Company to Pfizer, Inc. (NYSE: PFE). Background: On September 21, 2025, Metsera and Pfizer entered into a definitive merger agreement. Under the terms of the agreement, holders of Metsera’s common stock will receive $47.50 per share in cash. In a ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.Pfizer Inc. (NYSE: PFE ) announced today that it will acquire Metsera, Inc. (NASDAQ: MTSR ...

Pfizer Inc (NYSE:PFE) stock is up 2.6% to trade at $24.65 at last check, after the pharma giant revealed it will buy weight-loss drug company Metsera (MTSR) in a deal valued up to $7.3 billion.PFE is on track for its best single-day percentage gain since July as well as its third gain in the last four sessions. A ceiling at the $25 level remains after in late August the stock pulled back form a rally to its highest level since March, however. In the last 12 months, the equity shed 16.5%.Options bulls are ch ...

(Bloomberg) -- Pfizer Inc. will pay $4.9 billion for the obesity startup Metsera Inc. in a bid to catch up to rival drugmakers after failing to compete with its own weight-loss medications.The US drugmaker agreed to buy Metsera for $47.50 in cash per share, and further payments of up to $22.50 per share if three specific and regulatory milestones are met, it said Monday, with a total potential value of $7.3 billion. The deal represents a 43% premium to Metsera’s closing share price on Friday. Also Read | TC ...

收购交易核心信息 - 辉瑞以49亿美元预付款收购心血管代谢药物开发商Metsera 可能支付约24亿美元里程碑付款 总估值最高达73亿美元 交易预计2025年第四季度完成 [1] - Metsera总部位于纽约 今年刚登陆纳斯达克上市 收购消息宣布后其股价单日暴涨超60% [1] 市场影响与股价反应 - 收购传闻导致A股两只减肥药概念股9月22日股价大跌 博瑞医药下跌13.15% 众生药业下跌6.28% [1] - 市场猜测股价大跌原因是两家企业减重药物管线失去辉瑞这一潜在收购方 [1] 收购战略动机 - 辉瑞看中Metsera在GLP-1和淀粉样肽类别中的长效注射剂研发管线及口服肽开发项目 [2] - Metsera主打药物MET-097i为每月一次GLP-1受体激动剂 处于临床二期试验 另有两款口服GLP-1 RA候选药物即将进入临床试验 [2] - 收购符合辉瑞聚焦最具影响力投资领域的战略 推动公司进入心血管代谢关键治疗领域 [3] 行业研发趋势 - GLP-1药物因显著减肥效果受全球追捧 但需长期使用以防体重反弹 [2][3] - 研发核心方向转向长效化、多靶点和口服药物 以满足更便捷有效的需求 [3] - 辉瑞曾开发口服小分子GLP-1药物Lotiglipron和Danuglipron 但因肝损伤问题先后于2023年和2024年4月终止开发 [2] 公司战略表态 - 辉瑞将运用心血管代谢疾病领域积累 结合生产与商业化网络 加速推进Metsera管线 [3] - Metsera临床数据显示卓越疗效、耐受性及长效性 支持每月一次给药方案 有望解决肥胖领域未满足医疗需求 [3]

Stephen Miran, the new Fed governor backed by President Trump, will speak Monday in New York. Fed Chair Jerome Powell will speak Tuesday. More Fed members will speak later this week. Miran has promised to share his policy views during his first appearance as governor in New York. Markets are also waiting for Friday’s Personal Consumption Expenditures (PCE) inflation data, which is the Fed’s favorite inflation measure, as per Yahoo Finance. If the PCE report is weak, it could raise chances of another quarte ...